Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Kinross Gold Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.83 (market cap $4.49B), while Kinross Gold Corporation trades at $23.02 (market cap $28.53B). The key difference: Kinross Gold Corporation is far larger — about 6.4× ACADIA Pharmaceuticals Inc.'s market cap, and Kinross Gold Corporation pays a 0.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KGC | |
|---|---|---|
Market Cap | $4.49B | $28.53B |
Sector | Health | Basic Materials |
52-Week High | $28.06 | $38.06 |
52-Week Low | $20.06 | $15.19 |
Enterprise Value | $3.69B | $27.08B |
Dividend Yield | — | 0.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Kinross Gold (KGC) trades at $23.87, down 3.4% over 24 hours amid a bearish technical signal. The company demonstrates strong fundamentals with revenue growing from $3.5B in 2022 to $7.05B in 2025 and net income surging to $2.39B. Recent quarters show consistent earnings beats, with Q2 2026 results expected on July 29. Analyst consensus remains bullish with a $35.33 price target representing 48% upside potential.
KGC presents a compelling value opportunity with attractive valuation ratios (P/E 10.52, EV/EBITDA 5.46) and robust profitability (35.99% net margin). Key risks include gold price volatility and rising operational costs. The company's strong cash flow generation and growth projects support long-term upside, though technical indicators suggest near-term consolidation may continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
